Prostate Cancer

... CFD Therapeutics Formed to Advance Novel Monoclonal Antibodies for Cancer CFD Therapeutics Formed to Advance Novel Monoclonal Antibodies for Cancer SOUTH SAN FRANCISCO, Calif., March 30 /PRNewswire/ - diaDexus, Inc.

and San Francisco-based Biotechnology Value Fund L.P.

(BVF) today jointly announced the formation of a new spin-out company, CFD Therapeutics, Inc.

(CFD), to develop novel cancer therapeutics stemming from discoveries made previously by diaDexus.

CFD will specifically focus on the development of therapeutic monoclonal antibodies directed against proprietary ovarian, pancreatic, breast, colon, prostate and lung cancer targets licensed from diaDexus.

BVF has made an initial investment in CFD, through which it has assumed majority ownership in the company.

diaDexus provided an exclusive license to CFD for its entire portfolio of therapeutic targets and associated monoclonal antibodies.

CFD's programs will leverage over eight years and more than $100 million of novel target discovery and antibody development efforts carried out at diaDexus.

Through its founding partnership with Incyte Genomics in 1997 and its own discovery program, diaDexus identified genes that are highly over-expressed in cancerous relative to normal tissue.

Starting from thousands of candidate genes, diaDexus identified approximately 20 promising candidates to move forward into pre-clinical development as therapeutic antibody targets.

"We have selected ...

Read more...